Freemont Management S.A. Bristol Myers Squibb CO Transaction History

Freemont Management S.A.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	SELL	$57.89 - $64.73 $833,616 - $932,112	-14,400 Reduced 14.44%	85,300 $4.95 Million
Q3 2022 Nov 07, 2022	SELL	$0.13 - $76.84 $325 - $192,100	-2,500 Reduced 2.45%	99,700 $7.09 Million
Q2 2022 Jul 29, 2022	SELL	$72.62 - $79.98 $377,624 - $415,896	-5,200 Reduced 4.84%	102,200 $7.87 Million
Q1 2022 May 06, 2022	BUY	$61.48 - $73.72 $6.6 Million - $7.92 Million	107,400 New	107,400 $7.84 Million
Q4 2021 Feb 07, 2022	SELL	$53.63 - $62.52 $8.31 Million - $9.68 Million	-154,900 Closed	0 $0
Q3 2021 Nov 04, 2021	BUY	$59.17 - $69.31 $35,502 - $41,586	600 Added 0.39%	154,900 $9.17 Million
Q4 2020 Feb 16, 2021	BUY	$57.74 - $65.43 $8.91 Million - $10.1 Million	154,300 New	154,300 $9.57 Million

2,428

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Freemont Management S.A., based on Form 13F filings with the SEC.

Stay updated on Freemont Management S.A. with notifications on news.